Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Conclusions/interpretationPrecision medicine approaches can facilitate effective individualised treatment choice between SGLT2i and GLP1-RA therapies, and the use of routinely collected clinical features for treatment selection could support low-cost deployment in many countries.Graphical Abstract
Source: Diabetologia - Category: Endocrinology Source Type: research
More News: Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | Primary Care | Scotland Health | SGLT2 Inhibitors | Sodium | Urology & Nephrology | Victoza | Women